Angiopeptin [clinicaltrials_resource:b5a22ed6a8d78563379b89fd804db18f]
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome [clinicaltrials:NCT00092287]Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction [clinicaltrials:NCT00145405]Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [clinicaltrials:NCT00210457]Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis [clinicaltrials:NCT00216372]Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR [clinicaltrials:NCT00216398]Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly [clinicaltrials:NCT00234572]Lanreotide (Somatuline Autogel) in Thyroid-Associated Ophthalmopathy Treatment [clinicaltrials:NCT00288522]Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours [clinicaltrials:NCT00326469]clinicaltrials:NCT00353496Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [clinicaltrials:NCT00383708]Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly [clinicaltrials:NCT00444873]clinicaltrials:NCT00447499clinicaltrials:NCT00495846Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly [clinicaltrials:NCT00499993]Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) [clinicaltrials:NCT00517491]Treatment of the Dumping Syndrome With Lanreotide Autogel® [clinicaltrials:NCT00543179]Lanreotide as Treatment of Polycystic Livers [clinicaltrials:NCT00565097]clinicaltrials:NCT00627796Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer [clinicaltrials:NCT00630695]clinicaltrials:NCT00681187clinicaltrials:NCT00686348clinicaltrials:NCT00690898Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects [clinicaltrials:NCT00701363]clinicaltrials:NCT00703079Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae [clinicaltrials:NCT00729313]clinicaltrials:NCT00771888clinicaltrials:NCT00774930Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour [clinicaltrials:NCT00842348]clinicaltrials:NCT00891371Lanreotide Levels in Acromegaly [clinicaltrials:NCT00916916]clinicaltrials:NCT00993356Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy [clinicaltrials:NCT01070758]Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients [clinicaltrials:NCT01076803]clinicaltrials:NCT01137682Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients [clinicaltrials:NCT01313273]clinicaltrials:NCT01315795clinicaltrials:NCT01354405Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma [clinicaltrials:NCT01372007]clinicaltrials:NCT01538966clinicaltrials:NCT01616927
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Angiopeptin [clinicaltrials_resource:b5a22ed6a8d78563379b89fd804db18f]
Bio2RDF identifier
b5a22ed6a8d78563379b89fd804db18f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b5a22ed6a8d78563379b89fd804db18f
identifier
clinicaltrials_resource:b5a22ed6a8d78563379b89fd804db18f
title
Angiopeptin
@en
type
label
Angiopeptin [clinicaltrials_resource:b5a22ed6a8d78563379b89fd804db18f]
@en